Prostatype Genomics AB Statistics
Total Valuation
PGABF has a market cap or net worth of 10.87 million. The enterprise value is 9.42 million.
| Market Cap | 10.87M |
| Enterprise Value | 9.42M |
Important Dates
The last earnings date was Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 59.19M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2,474.32% |
| Shares Change (QoQ) | +669.75% |
| Owned by Insiders (%) | 4.70% |
| Owned by Institutions (%) | n/a |
| Float | 56.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 144.51 |
| PB Ratio | 2.83 |
| P/TBV Ratio | 12.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.98 |
| EV / Sales | 117.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.29 |
Financial Position
The company has a current ratio of 1.95
| Current Ratio | 1.95 |
| Quick Ratio | 1.93 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.55 |
Financial Efficiency
Return on equity (ROE) is -182.06% and return on invested capital (ROIC) is -104.28%.
| Return on Equity (ROE) | -182.06% |
| Return on Assets (ROA) | -68.19% |
| Return on Invested Capital (ROIC) | -104.28% |
| Return on Capital Employed (ROCE) | -113.80% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 12,532 |
| Profits Per Employee | -794,059 |
| Employee Count | 6 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 119.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,950 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PGABF had revenue of 75,189 and -4.76 million in losses. Loss per share was -0.50.
| Revenue | 75,189 |
| Gross Profit | -2.22M |
| Operating Income | -4.37M |
| Pretax Income | -4.76M |
| Net Income | -4.76M |
| EBITDA | -4.34M |
| EBIT | -4.37M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 1.36 million in cash and n/a in debt, with a net cash position of 1.36 million.
| Cash & Cash Equivalents | 1.36M |
| Total Debt | n/a |
| Net Cash | 1.36M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.84M |
| Book Value Per Share | 0.10 |
| Working Capital | 737,588 |
Cash Flow
In the last 12 months, operating cash flow was -4.06 million and capital expenditures -54,052, giving a free cash flow of -4.11 million.
| Operating Cash Flow | -4.06M |
| Capital Expenditures | -54,052 |
| Free Cash Flow | -4.11M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,806.85% |
| Pretax Margin | -6,336.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PGABF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,474.32% |
| Shareholder Yield | -2,474.32% |
| Earnings Yield | -43.85% |
| FCF Yield | -37.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |